Lv7
5000 积分 2022-03-17 加入
Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE ‐042 China study
9天前
已完结
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
1个月前
已完结
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
1个月前
已完结
Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
1个月前
已完结
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial
1个月前
已完结
Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial
1个月前
已完结
Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck
1个月前
已完结
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
1个月前
已完结
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
1个月前
已完结
Efficacy and Safety of Different Neoadjuvant Treatment Regimens in Locally Advanced Squamous Head and Neck Cancer
1个月前
已完结
皖公网安备34019202002308
